75 Second Avenue, Suite 605
Needham, MA 02494
Phone: (617) 454-1199
Bioxytran, Inc. (“Bioxytran” or “the Company”) is a clinical stage pharmaceutical company developing therapeutics in two areas: (1) glycovirology and anti-viral therapeutics; and (2) hypoxic conditions, necrosis, and degenerative diseases. Bioxytran’s glycovirology efforts, conducted through its subsidiary, Pharmalectin Inc., are focused on developing a novel technology platform—ProLectin—designed to reduce the viral load and modulate the immune system through galectin-3 inhibition. Galectin-3 inhibitors have the capability to bind with proteins on the surface of a virus, preventing the virus from attaching to and entering the cell. Using its ProLectin technology platform, Bioxytran is developing a group of therapeutic candidates that provide an end-to-end solution for COVID-19, including treatment for severe conditions derived from the disease. The Company’s lead candidate, ProLectin-M, is a chewable tablet for treating mild-to-moderate COVID-19 that binds with the spike proteins on the virus’ surface and acts as a cell-entry inhibitor. With an initial focus on COVID-19, Bioxytran believes that its technology can be used to create therapeutics targeting a considerable number of viruses, as well as the potential creation of a single molecule designed to target multiple receptors responsible for various aspects of a disease. Bioxytran’s second technology platform—its hypoxia program—relies on the application of its proprietary co-polymer chemistry manufacturing process to enhance the hemoglobin molecule, creating an injectable intravenous drug that prevents necrosis by carrying oxygen to brain cells that have limited or blocked blood flow. Bioxytran’s lead candidate in this research area is BXT-25, an oxygen-carrying small molecule intended to treat hypoxic conditions in the brain resulting from stroke. BXT-25 development is on hold pending the raise of additional capital.
* The Corporate Snapshot was last updated on August 26, 2022.